Advertisement
Organisation › Details
Boehringer Ingelheim S.A. (Spain)
Start | 1997-02-01 existent | |
Group | Boehringer Ingelheim (Group) | |
Industry | pharmaceutical | |
Region | Barcelona | |
Country | Spain (España) | |
City | n. a. Barcelona | |
Address record changed: 2023-07-12 | ||
Basic data | Employees | n. a. |
Record changed: 2023-07-10 |
Advertisement
More documents for Boehringer Ingelheim (Group)
- [1] Boehringer Ingelheim. (4/9/24). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets". Ingelheim & Shanghai....
- [2] Enara Bio Ltd.. (1/4/24). "Press Release: Boehringer Ingelheim Licenses Multiple Dark Antigens from Enara Bio to Develop Off-the-Shelf Immunotherapies for Non-small Cell Lung Cancer (NSCLC)". Oxford....
- [3] Boehringer Ingelheim. (1/4/24). "Press Release: Boehringer Ingelheim and 3T Biosciences Enter into a Second Partnership to Develop Next-generation Cancer Immunotherapies". Oxford....
- [4] Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan....
- [5] AC Immune S.A.. (12/15/23). "Press Release: AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO". Lausanne....
- [6] Boehringer Ingelheim. (11/28/23). "Press Release: Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development". Ingelheim & Armonk, NY....
- [7] Boehringer Ingelheim. (11/22/23). "Press Release: Boehringer Ingelheim Expands Immuno-oncology Portfolio with the Acquisition of Bacterial Cancer Therapy Specialist T3 Pharma". Ingelheim & Basel....
- [8] Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow....
- [9] Burning Rock Biotech Ltd.. (10/31/23). "Press Release: Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics"....
- [10] Boehringer Ingelheim. (10/2/23). "Press Release: Boehringer Ingelheim to Start Phase 1 Development of BI 771716 – a Potential New Treatment for Geographic Atrophy, a Leading Cause of Blindness Worldwide". Ingelheim & Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top